• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
CAO Bin,BI Jianjie.Clinical efficacy of Xinmailong Injection combined with western medicine in the treatment of patients with coronary heart disease and heart failure and the effect of plasma NT-proBNP[J].Journal Of Pharmaceutical Research,2021,40(1):60-61[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2535times   Download 2592次 QR Code for this article
Scan with your phone!
心脉隆注射液联合西药应用于冠心病心力衰竭患者治疗的临床疗效及血浆NT-proBNP的影响
曹彬1,毕建杰2
Font:Larger+|Default|Smaller-
(1.博兴县人民医院,山东 博兴 256500;2.山东明仁福瑞达制药股份有限公司,山东 济南 250104)
摘要:
目的 对于冠心病心力衰竭患者,探究实施西药+心脉隆注射液共同治疗对血浆NT-proBNP以及临床疗效的影响。方法 本次研究随机挑选1年内(2019年02月至2020年02月)到院治疗的冠心病心力衰竭患者70例进行研究,根据实施治疗方式不同将其分为35例基础组和35例实验组。将西药用于治疗35例基础组患者,将西药+心脉隆注射液用于治疗35例实验组患者。分别对2组患者治疗前后血浆NT-proBNP 水平变化情况以及临床疗效进行比对。 结果 治疗后与实验组相对比,参照组患者血浆NT-proBNP水平显著偏高,(P<0.05);治疗后与实验组相对比,参照组患者总有效率显著偏低,(P<0.05)。结论 将血浆NT-proBNP 水平联合用于治疗临床收治的冠心病心力衰竭患者,可显著提升整体临床疗效,同时改善患者血浆NT-proBNP 水平。
关键词:  冠心病  心力衰竭  西药  心脉隆注射液
DOI:10.13506/j.cnki.jpr.2021.01.012
基金项目:
Clinical efficacy of Xinmailong Injection combined with western medicine in the treatment of patients with coronary heart disease and heart failure and the effect of plasma NT-proBNP
CAO Bin1,BI Jianjie2
(Boxing People’s Hospital,Boxing 256500,China)
Abstract:
Objective To explore the effect of western medicine plus Xinmailong Injection on plasma NT-proBNP and clinical efficacy in patients with coronary heart disease and heart failure.Methods This study randomly selected 70 patients with coronary heart disease and heart failure who came to hospital for treatment within one year (February 2019 to February 2020) and divided them into 35 basic groups and 35 experimental groups according to different treatment methods. Western medicine was used to treat 35 patients in the basic group and western medicine+Xinmailong injection was used to treat 35 patients in the experimental group. The changes of plasma NT-proBNP level and clinical efficacy of the two groups were compared before and after treatment respectively.Results Compared with the experimental group, the plasma NT-proBNP level in the reference group was significantly higher (p < 0.05). Compared with the experimental group after treatment, the total effective rate in the reference group was significantly lower (P<0.05).Conclusion The combination of plasma NT-proBNP level and clinical treatment for patients with coronary heart disease and heart failure can significantly improve the overall clinical efficacy and improve the plasma NT-proBNP level of patients.
Key words:  Coronary Heart Disease  Heart failure  Western medicine  Xinmailong injection
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.